Loading...
•
Jun 30, 2022
Aldeyra Q2 2022 Earnings Report
Reported financial results for the second quarter of 2022 and provided recent corporate highlights.
Key Takeaways
Aldeyra Therapeutics reported a net loss of $17.8 million for the three months ended June 30, 2022. The company's cash, cash equivalents, and marketable securities totaled $196.7 million as of June 30, 2022.
Pre-NDA meeting with the FDA scheduled for Q3 2022 to discuss NDA submission of Reproxalap for dry eye disease.
Pre-NDA meeting with the FDA planned for the second half of 2022 to discuss NDA submission of ADX-2191 for primary vitreoretinal lymphoma.
Top-line results from Phase 3 GUARD trial of ADX-2191 in proliferative vitreoretinopathy expected in the second half of 2022.
Top-line results from Phase 2 clinical trial of oral RASP modulator ADX-629 in acute alcoholic hepatitis expected in the second half of 2022.
Aldeyra
Aldeyra
Forward Guidance
Aldeyra believes that existing cash, cash equivalents, and marketable securities will be sufficient to fund currently projected operating expenses through the end of 2023.
Positive Outlook
- Planned NDA submissions for reproxalap and ADX-2191
- Potential initial commercialization of reproxalap and ADX-2191, if approved
- Continued development of Aldeyra’s product candidates in ocular and systemic immune-mediated diseases
- Sufficient funds to cover operating expenses through the end of 2023
- Advancing clinical trials for multiple product candidates